tbuckley/cabot-search huggingface dataset:
PTU-044 Improved Diagnostic Yield with Cell Block Only Preparation of EUS Guided FNA Specimens
Authors: V Mahesh, J Kizhakkepatt, S Shaktawat
Journal: Gut (2016)

<h3>Introduction</h3> Recently increased attention has been paid to the post FNA processing of specimen including on site smear preparation or extruding the entire specimen into preservative for cytotechnician assisted cell block or smear preparation, to improve diagnostic yield (DY). Due to logistical and cost issues, many centres like ours, do not have rapid onsite smear evaluation facilities. <h3>Aim</h3> Comparative analysis of cell block only versus cell block and smear preparation of specimens acquired via standard EUS guided FNA technique. Secondary outcomes include assessment of cellularity of the specimens. <h3>Methods</h3> Retrospective case-note review study. Consecutive samples were evaluated from January 2010 to October 2015 at our institution. All FNA procedures involving solid lesions were included. Choice of needle was up to the discretion of the endosonographer. All specimens were fully extruded with saline/stylet into ‘Cytorich’<sup>TM</sup> containers, cytotechnician randomly decided regarding smear and cell block or cell block only preparation. Cellularity was graded simply as adequate or inadequate. <h3>Results</h3> 118 samples were collected from 112 patients, 69 male/43 female patients, and mean age of 64.1 ±9.6 years. Initial 49 FNAs were performed using Aloka alpha5 Olympus<sup>TM</sup> processor, rest with EU-ME2 Olympus<sup>TM</sup> processor. All the procedures were done by 4 experienced endosonographers and two trainees, following stadard technique. Average 3.89 ±0.47 passes, 5–20 mls of suction, stylet used only in the first pass. 40 samples were obtained with 19 G needles, 46 samples with 22 G, 7 samples with 25 G and 23 obtained using combination/core needles. 59 Solid pancreatic lesions, rest of them included lesions in the wall, lymph nodes, liver, pericardial, retroperitoneal etc. 33 cell block only (CB) and 85 smear plus cell block (SCB) were done. Greater number of CB samples (29/33, 87.8%) had adequate cellularity compared to SCB (68/85, 75.2%), ‘p’ value =0.059, cytological diagnosis was made more often with CB (29/33, 87.8%) compared to SCB (64/85), p = 0.071. No statistical significance was seen in univariate or multivariate logistic regression analysis for tumour size(≥2 cm), route of FNA (transoesophageal, transgastric or transduodenal) or size of needle (19 G, 22 G or 25 G). <h3>Conclusion</h3> Our study shows better diagnostic yield when the entire specimen was processed exclusively as cell block only rather than split into smear initially and remnant tissue for cell block preparation. Cell block alone preparation also preserves more material for immunohistochemistry and more advanced DNA analysis techniques. Limitations include the retrospective nature of study, variable operator and cytopathologist experience and ever improving FNA techniques (use of elastography, newer EUS processor). <h3>Disclosure of Interest</h3> None Declared
Platelet Transfusion Requirement during ASCT for Lymphoma Is a Powerful Prognostic Variable.
Authors: Hien Duong, Lisa Rybicki, John Sweetenham, Brad Pohlman, Ronald Sobecks, Robert Dean, Edward Copelan, Steven Andresen, Stephen Smith, Shawnda Sungren, Josephine Chan, Brian Bolwell
Journal: Blood (2008)
Dasatinib or High-Dose Imatinib for Patients with Chronic-Phase Chronic Myeloid Leukemia Resistant to Standard-Dose Imatinib: 2-Year Follow-Up Data from START-R (CA180-017).
Authors: Hagop M. Kantarjian, Philippe Rousselot, Ricardo Pasquini, Nelson Hamerschlak, Jerzy Holowiecki, David Dejardin, Eric Bleickardt, Neil P. Shah
Journal: Blood (2007)
Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia
Authors: Matthew John Jerome Rose-Zerilli, Helen Parker, Marta Larrayoz, Ruth Clifford, Stuart Blakemore, Jennifer Edelmann, Jane Gibson, Jun Wang, Viktor Ljungstrom, Tracy Chaplin, Ali Roghanian, Zadie Davis, Anton Parker, Eugen Tausch, Stavroula Ntoufa, Sara Ramos, Pauline Robbe, Andrew J Steele, Graham Packham, Ana E. Rodriguez, Lee Brown, Feargal McNicholl, Francesco Forconi, Andrew R Pettitt, Peter Hillmen, Martin J.S. Dyer, Mark S Cragg, Bryan D Young, Claude Chelala, Richard Rosenquist, Kostas Stamatopoulos, Stephan Stilgenbauer, Samantha Knight, Anna Schuh, David Oscier, Jonathan C Strefford
Journal: Blood (2015)
PTU-098 Improving PEG Completion Rates: Adoption of an Algorithm to Maximise Success: An 18 Month Single-Centre Review
Authors: J Frost, A Dhanda, J Ratcliffe, N Fisher
Journal: Gut (2016)

<h3>Introduction</h3> Percutaneous endoscopic gastrostomy (PEG) placement is an established technique for nutritional support, with a procedural success rate around 95% in most case series.<sup>1</sup> Failed procedures generally need alternative surgical or radiolofical approaches. In recent years we have adopted an algorithm for maximising PEG placement success rate and have now reviewed our outcomes. <h3>Methods</h3> Referrals are vetted by the nutrition support team before selection and cases accepted for PEG are listed on a consultant gastroenterologist’s list. The preferred procedural algorithm is: 1 A standard PEG technique is used with finger indentation and a safe-track technique; transillumination not considered necessary. 2 Trochar insertion into the stomach is assisted by counter-traction on the surrounding mucosa with a snare if necessary. 3 If this doesn’t help then the PEG trochar +/- sheath are removed and a long drainage access (kellett) needle is passed to assist gastric puncture. 4 If the PEG is unsuccessful, then a further attempt on another day is considered with another endoscopist if necessary. For this review, the nutrition team, endoscopy and clinical databases were reviewed for all patients accepted for PEG placement for 18 months from July 2014 onwards. Outcome measures included PEG success rates, techniques used, procedural complications and 30 day mortality. <h3>Results</h3> 154 patients were accepted for first PEG placement. Five patients did not proceed to PEG attempt owing to death or swallowing recovery. In the 149, all patients (100%) achieved successful PEG insertion at first or second attempt. Most cases (140/149, 94%) were done with the standard pull-through technique. In 6 cases (4%) a Kellett needle was used. In 3 cases (2%) a second endoscopy procedure was required for PEG completion: in 2/3 of these cases, initial failure was attributed to inadequate trans-illumination but successful completion was later done by another endoscopist. In the third case the oesophagus could not be intubated due to a large pharyngeal pouch; this was later overcome with the help of an oesophageal guidewire placed under fluoroscopic guidance. There were no identified procedural complications and overall 30 day mortality was 9%. <h3>Conclusion</h3> The procedural algorithm we have described for PEG placement, which excludes the need for transillumination, includes optional usage of a long drainage access needle and considers a second endoscopy procedure if the first procedure fails, led to a 100% completion rate in this case series. Adoption of this approach may therefore minimise the need for other higher-risk alternatives. <h3>Reference</h3> 1 Potack JZ, Chokhavatia S. Complications of and controversies associated with PEG: Report of a case and literature review. <i>Medscape J Med</i> 2008;<b>10</b>(6):142. <h3>Disclosure of Interest</h3> None Declared
Protective Role of ADAMTS13 for Myocardium in Mouse Model of Experimental Myocardial Infarction.
Authors: Masaaki Doi, Hideto Matsui, Yukiji Takeda, Yoshihiko Saito, Maiko Takeda, Yasunori Matsunari, Kenji Nishio, Midori Shima, Fumiaki Banno, Masashi Akiyama, Koichi Kokame, Toshiyuki Miyata, Mitsuhiko Sugimoto
Journal: Blood (2012)
Gene Expression Profiles in Acute Myeloid Leukemias (AML): A Novel Approach Using SAGE and Custom Microarray.
Authors: Sanggyu Lee, JianJun Chen, Guolin Zhou, Edward Touma, Run Shi, Miao Sun, Masha Kocherginsky, Theodore G. Karrison, Yeong C. Kim, Xijin Ge, Nimanthi Jayathilaka, Nimmi Emmanuel, Gerard Bouffard, Nicole Dietrich, Alice Young, Eric Green, Pu Paul Liu, Ximin Li, San Ming Wang, Janet D. Rowley
Journal: Blood (2004)
Mitochondrial NADP+-Dependent Isocitrate Dehydrogenase Deficiency Exacerbates Mitochondrial and Cell Damage after Kidney Ischemia-Reperfusion Injury
Authors: Sang Jun Han, Hee-Seong Jang, Mi Ra Noh, Jinu Kim, Min Jung Kong, Jee In Kim, Jeen-Woo Park, Kwon Moo Park
Journal: Journal of the American Society of Nephrology (2016)

Mitochondrial NADP+-dependent isocitrate dehydrogenase (IDH2) catalyzes the oxidative decarboxylation of isocitrate to α-ketoglutarate, synthesizing NADPH, which is essential for mitochondrial redox balance. Ischemia-reperfusion (I/R) is one of most common causes of AKI. I/R disrupts the mitochondrial redox balance, resulting in oxidative damage to mitochondria and cells. Here, we investigated the role of IDH2 in I/R-induced AKI. I/R injury in mice led to the inactivation of IDH2 in kidney tubule cells. Idh2 gene deletion exacerbated the I/R-induced increase in plasma creatinine and BUN levels and the histologic evidence of tubule injury, and augmented the reduction of NADPH levels and the increase in oxidative stress observed in the kidney after I/R. Furthermore, Idh2 gene deletion exacerbated I/R-induced mitochondrial dysfunction and morphologic fragmentation, resulting in severe apoptosis in kidney tubule cells. In cultured mouse kidney proximal tubule cells, Idh2 gene downregulation enhanced the mitochondrial damage and apoptosis induced by treatment with hydrogen peroxide. This study demonstrates that Idh2 gene deletion exacerbates mitochondrial damage and tubular cell death via increased oxidative stress, suggesting that IDH2 is an important mitochondrial antioxidant enzyme that protects cells from I/R insult.
SP0017 The Effect of Non-Pharmacological Interventions for Hand OA
Authors: J. Arokoski
Journal: Annals of the Rheumatic Diseases (2016)

The hand is a common site of peripheral osteoarthritis (OA). The most common sites for hand OA are distal and proximal interphalangeal joints and the base of the thumb. Because the natural history of hand OA is poorly understood and there is no preventive treatment or cure after the onset of development, the goal of OA treatment is the management and alleviation of pain as well as the maintenance and improvement of functional capacity. Many non-pharmacological treatments, including patient education, assistive technology, splinting, therapeutic exercises and physical therapies, has been used to treat patients with hand OA. This presentation will provide an overview the principles of these treatment methods and the scientific evidence supporting the efficacy of these treatments in relieving pain and improving function. <h3>Disclosure of Interest</h3> None declared
FRI0477 A Modified Version of The Psoriatic Arthritis Disease Activity Score (MPASDAS) Using Sf-12 as A Measure of Quality of Life May Be More Feasible in Clinical Practice
Authors: V. Chandran, M. Got, S. Li, A.V. Perruccio, D.D. Gladman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Psoriatic Arthritis Disease Activity Score (PASDAS) is a newly developed composite disease activity measure that summarizes psoriatic arthritis (PsA) disease activity with a score ranging from 0–10. PASDAS captures articular and extra-articular manifestations of the disease and the impact of the disease on the patient via the following variables: swollen and tender joints, dactylitis, Leeds enthesitis index, C-reactive protein, Health Assessment Questionnaire, physician and patient global disease activity, and the physical component summary score (PCS) of the medical outcomes survey Short Form 36 (SF-36). A limitation of PASDAS is that the score depends on the patient completing the SF-36, which requires a significant amount of time to complete. A shorter 12-question subset of SF-36, the SF-12, with the same range of values, agrees well with the SF-36 in many patient populations. <h3>Objectives</h3> The objective was to measure the agreement between PASDAS calculated using the standard scoring formula and mPASDAS calculated by replacing the SF-36-PCS with SF-12-PCS. <h3>Methods</h3> 100 PsA patients attending the University of Toronto PsA clinic for follow-up visits were consecutively recruited in June and July 2015. All variables required to calculate PASDAS were collected and PASDAS was calculated for each patient. The 12 item responses for SF-12 were extracted from the SF-36 questionnaires. A mPASDAS score was subsequently calculated based on the PASDAS scoring formula where SF-36 –PCS is replaced by SF-12 - PCS. A Bland-Altman plot of the differences in scores calculated via PASDAS and mPASDAS measured agreement between the two sets of scores. The rate of missclassification when categorizing the patient9s disease activity state as high, moderate or low using the mPASDAS instead of PASDAS was also examined. <h3>Results</h3> The analysis [N=100, 53% male, mean (SD) age 57.3 (11.9) years, mean (SD) disease duration 16.9 (11.7) years] revealed that the mean (SD) PASDAS was 3.29 (1.39) and the mean (SD) mPASDAS was 3.24 (1.27). The Bland-Altman plot showed a mean difference (95%CI) between mPASDAS and PASDAS of -0.05 (-0.07, -0.03). The lower limit and upper limits of the difference was (-0.24 [95%CI -0.21, -0.28]) and 0.14 [0.10, 0.17]), respectively. Five (5%) patients were misclassified (4 to the lower disease activity category) when mPASDAS was used instead of PASDAS. <h3>Conclusions</h3> mPASDAS and PASDAS shows strong agreement without clinically significant systematic bias in mPASDAS scores. In clinical settings, the mPASDAS may replace PASDAS in disease activity assessment given the strong agreement and low misscalssification rate along with significantly reduced questionnaire burden. <h3>Disclosure of Interest</h3> None declared
OP0018 Hyperuricemia Increases Mortality Only in Patients with Gout and Existing Cardiovascular Disease. A Prospective Analysis from The Busselton Health Study
Authors: J. Nossent, W. Raymond, M. Divitini, L. Host, M. Knuiman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hyperuricemia is increasingly prevalent and associated with cardiovascular disease [1]. While hyperuricemia can induce endothelial dysfunction, oxidative stress and inflammation uncertainty remains regarding the association between hyperuricemia and vascular events [2,3]. <h3>Objectives</h3> Investigate whether baseline and/or time averaged UA levels were associated with cardiovascular events and mortality in the Busselton Health Study (BHS) cohort. <h3>Methods</h3> Prospective study of the BHS cohort (n=4,171), using baseline serum UA measures and 15 year follow-up [4]. Outcomes included were cardiovascular events (CVE) and mortality, derived from State-wide registries. Hazard ratios (HR) for UA level as continuous and categorical (low, medium, high) predictor of outcomes, stratified for baseline cardiovascular disease and a history of gout were analysed by multivariate Cox regression. <h3>Results</h3> Hyperuricemia was present in 9.4% in participants free of CVE and 16.5% in those with CVE at baseline. In those free of CVE (n=3,475), a 0.1mmol/L rise in UA level was associated with increased mortality (HR 1.19, CI 1.04–1.36), cardiovascular mortality (HR 1.27, CI 1.03–1.57) and first CVE (HR 1.28, CI 1.13–1.44) after age &amp; sex adjustment. Hyperuricemia significantly increased the risk of a first CVE (HR 1.52, CI 1.13–2.04). However, adjustment for a range of traditional cardiovascular risk factors attenuated these associations. Results were similar for the subset of 2,139 participants using multiple UA measures over time. In the fully adjusted model, gout was a significant independent predictor of mortality only in participants with a history of CVE at baseline (HR 1.75; CI 1.04–2.95). <h3>Conclusions</h3> Hyperuricemia is highly prevalent in the Busselton region of Western Australia and independently increased the risk CVE or mortality events in those with existing CVE and gout. UA lowering therapy for CVE prevention is advisable for patients with a history of gout and CVE, but clearly not warranted in those with asymptomatic hyperuricemia. <h3>References</h3> Robinson, PC., et al., An Observational Study of Gout Prevalence and Quality of Care in a National Australian General Practice Population. Journal of Rheum., 2015 Kanbay, M., et al., The role of uric acid in the pathogenesis of human cardiovascular disease. Heart, 2013 van Durme, C., et al., Cardiovascular Risk Factors and Comorbidities in Patients with Hyperuricemia and/or Gout: A Systematic Review of the Literature. Journal of Rheum., 2014 Knuiman, MW., et al., Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: a prospective cohort study. Eur J Cardiovasc Prev Rehabil, 2009 <h3>Disclosure of Interest</h3> None declared
Mass Cytometry Based Classification of Inter- and Intra-Tumoral Heterogeneity in Diffuse Large B-Cell Lymphoma
Authors: Manabu Kusakabe, Xuehai Wang, Guillermo Simkin, Justin Meskas, Chaoran Zhang, Daisuke Ennishi, Robert Kridel, Merrill Boyle, Elizabeth Chavez, Stacy Hung, David W Scott, Christian Steidl, Randy D. Gascoyne, Ryan R. Brinkman, Andrew P Weng
Journal: Blood (2015)
AB0653 Gastric Antral Vascular Ectasia in Systemic Sclerosis Patients: Long-Term Prognosis and Treatment
Authors: Y. Braun-Moscovici, M. Braun, I. Hermesh, Y. Tavor, M. Naffaa, R. Beshara-Garzoz, K. Toledano, A.P. Rozin, A. Balbir-Gurman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gastric antral vascular ectasia (GAVE) is characterized by a pathognomonic endoscopic pattern, mainly represented by red spots either organized in stripes radially departing from pylorus, defined as "watermelon stomach", or arranged in a diffused-way, the so called "honeycomb stomach". In our previous work we found a prevalence of GAVE in 35% of systemic sclerosis (SSc) patients that had an upper gastrointestinal (GI) endoscopy for evaluation of symptoms. The main complication of GAVE is symptomatic anemia due to GI bleeding requiring blood transfusion. As the pathogenesis is unknown, the aim of the therapy is to decrease GI bleeding. Endoscopic therapy (endotherapy) is the mainstay of treatment with surgery reserved for severe refractory cases. The data on the efficacy of endotherapy and treatment requirements of SSc patients with GAVE is very limited. <h3>Objectives</h3> The aim of our study is to assess the treatment requirements of SSc patients with GAVE and the efficacy of endotherapy in particular. <h3>Methods</h3> Retrospective analysis of a prospectively maintained database of SSc patients followed in a tertiary referral center for SSc. Our cohort is part of the EUSTAR cohort. Statistical analysis: descriptive, student9s T test, Mann-Whitney test. <h3>Results</h3> Fifty SSc patients were diagnosed with GAVE. Seventeen patients (34%) suffered of symptomatic anemia and were treated with argon plasma coagulation (APC) for a mean (SD) of 4.5 (4.3) sessions per patient. The mean (SD) hemoglobin was 9.4 (1.7) gr% in the group who required endotherapy compared to 11.5 (1.3) in the group which did not need any intervention. Four patients needed more than 6 sessions of treatment. Mean (SD) follow up was 4.1 (2.4) years. Nine patients required a total of 73 packed blood cells units and another 4 had intravenous iron replacement. Four patients died during the first 2 years after diagnosis, none of them due to bleeding complications. None of the patients that survived more than 2 years required further endotherapy or blood transfusions. No significant complications of APC occurred. Interestingly, all those who survived,had received immunotherapy with cyclophosphamide or mycophenolate mofetil due to multisystem involvement and disease activity. <h3>Conclusions</h3> Long term survivors among SSc patients with GAVE had an excellent response to APC and did not require blood transfusions or endotherapy after 2 years follow up. All the long term survivors received immunotherapy. This observation might hint to the pathogenesis of GAVE in SSc. <h3>Disclosure of Interest</h3> None declared
Reconstitution of CD52-Negative CD4 T Cells after Alemtuzumab-Based T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Eva M Wagner, Aline N Lay, Sina Wenzel, Timo Schmitt, Julia Hemmerling, Abdo Konur, Klaus Bender, Christoph Huber, Wolfgang Herr, Ralf G Meyer
Journal: Blood (2008)
P0795 : Safety and efficacy of sofosbuvir-containing regimens in the French observational cohort ANRS CO22 HEPATHER
Authors: V. De Ledinghen, H. Fontaine, C. Dorival, M. Bourlière, D. Larrey, P. Marcellin, S. Lucier, V. Petrov-Sanchez, A. Diallo, J. Capeau, P. Carrieri, C. Larsen, J.-M. Pawlotsky, J.-C. Trinchet, F. Zoulim, P. Cacoub, J. Dubuisson, P. Mathurin, F. Negro, G.-P. Pageaux, Y. Yazdanpanah, L. Wittkop, J.-P. Zarski, F. Carrat, S. Pol
Journal: Journal of Hepatology (2015)
Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma
Authors: Brad S. Kahl, Fangxin Hong, Michael E Williams, Randy D. Gascoyne, Lynne I Wagner, John C. Krauss, Sandra J. Horning
Journal: Blood (2011)
Combination Therapy of Selinexor with Bortezomib or Carfilzomib Overcomes Drug Resistance to Proteasome Inhibitors (PI) in Human Multiple Myeloma
Authors: Daniel M Sullivan, Trinayan Kashyap, Jana L Dawson, Yosef Landesman, Steven Grant, Kenneth H. Shain, Yun Dai, Michael Kauffman, Sharon Shacham, Joel G Turner
Journal: Blood (2015)
FRI0652-HPR Spinal Mobility in Long Standing Ankylosing Spondylitis. Application of Newly Developed Reference Intervals on Clinical Data
Authors: B. Sundström, L. Ljung, S. Wållberg-Jonsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> A hallmark of ankylosing spondylitis (AS) is the progressive decline of spinal mobility. Recently published reference intervals (RI) for spinal mobility measurements in healthy individuals offer new possibilities to assess impairment during the course of the AS disease (1). <h3>Objectives</h3> To evaluate the development of subnormal spinal mobility among patients with AS with regards to disease duration. <h3>Methods</h3> The cohort comprised all patients born 1937 or later with a validated (modified NY criteria) AS diagnosis 1980–2015 at the Rheumatology department in Västerbotten, whom had one or more registered spinal mobility measurement (n=232). The first subnormal value (lower than the 2.5th percentile of healthy individuals) regarding 10 cm Schober test, lateral spinal flexion, chest expansion, and cervical rotation, respectively, using the age-, sex- and length specific reference intervals, was defined as outcome. The follow-up started at the first measurement and ended at the date of the outcome, the study end (June 30, 2015), death or the time point for the last visit + 2 years. The results were presented by Kaplan-Meier curves. <h3>Results</h3> The median (range) of the total disease duration during follow-up was 31 (5–61) years. 3706 examinations were evaluated, with a median of 24 examinations/patient, or median (range) 1.0 (0.1–2.8) examinations/year of follow-up. The proportion of patients with subnormal mobility increased by disease duration for all measurements. Lumbar mobility was most impaired, but after 15–20 years half of the patients still had mobility measurements within the normal range (Figure 1). <h3>Conclusions</h3> Preserved spinal mobility is common in long-standing AS. However, the results indicated a continuous progression of spinal stiffness also after 20 years of AS disease. <h3>References</h3> Ramiro S, van Tubergen A, Stolwijk C, et al. Ann Rheum Dis 2015;74:1218–1224. <h3>Disclosure of Interest</h3> B. Sundström: None declared, L. Ljung Paid instructor for: Educational activities for BMS, Pfizer. Abbvie, S. Wållberg-Jonsson: None declared